14 Jun 2024


FluoGuide prioritizes a direct dialogue with our shareholders and investors. Besides public presentations, FluoGuide also has meetings with individuals or groups of investors regularly.

New - New exchange: Nasdaq First North

FluoGuide is moving from Spotlight to Nasdaq First North. Shareholders are strongly encouraged to make sure they will be able to freely trade their shares in the future.

- Presentations

Annual report interview with Redeye

28 February 2024

FluoGuide introduction with HC Andersen Capital

28 February 2024

Redeye Fight Cancer 2024

24 January 2024

Strategy update with SEB

15 January 2024

Redeye interview on strategy update

10 January 2024

Redeye Life Science Day

23 November 2023

Redeye interview on topline data from ph IIb in aggressive brain cancer

14 November 2023

Interview with Dansk Aktionærforeningen (in Danish)

10 November 2023

Redeye interview on topline data from ph IIa in head and neck cancer

8 November 2023

Interview with Redeye

30 October 2023

Redeye Medtech & Diagnostics Seminar

26 September 2023

Interview with Redeye on Q2 report

30 August 2023

Presentation and Q&A on Directed Share Issue

6 July 2023

Should you have any further questions regarding the directed share issue, feel free to send us an e-mail on

Interview with Redeye on clinical update

8 June 2023

Presentation at Redeye Growth Day

1 June 2023

Presentation at ABGSC Life Science Summit

30-31 May 2023

Presentation at Sedermeradagen in Stockholm

30 May 2023

Presentation at Redeye Orphan Drugs Event

26 April 2023

Redeye Exclusive interview on Annual Report

28 February 2023

Presentation at Økonomisk Ugebrev Life Science Investor Conference

22 February 2023

Dansk Aktionærforening interview (in Danish)

24 Januar 2023

Presentation at Redeye Fight Cancer Seminar

19 January 2023